Our providers help you think through movement in a realistic way
Typically, doctors follow FDA guidelines: GLP-1 agonists are approved for people with a BMI of 30 or above, or BMI of 27+ if you have conditions such as high blood pressure, high cholesterol, or type 2 diabetes [intermountainhealthcare.org]
The hypothalamic-pituitary-gonadal axis downregulates
So far, no specific menstrual or reproductive issue has been identified as a common side effect of these drugs
In pharmacodynamic studies, tirzepatide demonstrated dose-dependent slowing of gastric emptying, with the effect being most pronounced during the early treatment period and showing some attenuation over time with continued use
Always consult with your physician before starting any new medications or making changes to your existing treatment plan